Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Market makers currently have posted very low numbers on both the bid and the offer side. This makes it difficult to either buy or sell any size without having a dramatic effect on the price in either direction. If Don still needs to sell some shares for his homestead, he should put it out on the offer side to see if anyone will bite.
The legal costs in a trademark infringement case including depositions, discovery etc can run around $500K. Pyros should take you advice. They should be considering this although to file for a new trademark does take some time.
You know that Prasco's major revenue stream started on Jan 1 and will not be reported until May when the last fiscal year report is posted. Your off the charts revenue predictions are suspect, since as a Jour Trader, you may be pumping to get a nice price for you day trades. Your activity on the other Board gives me pause.
That being said, if you are correct, we will all sing Happy Days Are Here Again.
The expectation of a $20 million quarter is troubling since it would represent a 33% increase from the last quarter which surprised most here. While Adderall is currently a very hot drug which has high demand, the amount of product a company can sell is limited by the API available and the DEA quota. My fear is that the company reports $15 million or so and the Street is disappointed as it would be considered flat from prior quarter rather than the comparison with the quarter a year ago.
The above average volume for the past month indicates that new eyes are on this company and that hopefully there is a major buyer(s) who is accumulating the stock from new homeowners.
Looks like Don now met the down payment.
Looks like your done at .196 and change. Good Luck with the funds.
No nasdaq no interest by buyers. Or...... buyer(s) is taking a pause to see if there are any weak hands willing to sell. Offers remain thin.
Now you ruined the secret.
If this allows margin, you will have to decide whether to by a Ferrari or a Lamborghini rather than pay interest on margin.
There is no timeline for a Judge to decide a motion to dismiss. Since the Magistrate took the position that the motion to dismiss should be granted based on technical flaw in the pleading, it would not surprise if the Judge affirmed the motion dismissing the case but allowed NWBO to replead which will cause a delay as the defendant would probably again move to dismiss. This case, albeit involving millions of dollars in damages, will not be decided for at least 1-2 years.
1 million traded an hour before the market opens.The proof is in the putting (sic).
The average daily volume last week was double the usual volume. Assuming most here have been holding most of their shares, it appears that new investors have found this gem and are taking a position.
Charts are useless since this stock is trading at levels it hasn't reached in 7 years. Fundamentally this is a vastly different company as it moved from abuse deterent technology anchored by the expectation that SequestOx would be approved, to be a major distributor of Adderall along with the filing for other major CNS drugs.
Ironically, the best thing to happen to Elite was the greed of Lannett which developed its own Adderall product and rescinded its distribution agreement with Elite causing Nasrat to make the decision to self distribute. Hiring Kirkov was an important step which changed both his life and the future of long time holders.
There is an unknown regarding the revenue stream that Elite will derive as manufacturers of Adderall for Prasco sales which commenced on January 1 and will not, with the exception of products shipped for their launch prior to the start of the new year, be reflected in the quarter to be reported in February. If the positive predictions of some here that the company can do $60-90M in revenue in 2024 are true, who knows where this stock price can go with a PE which may also anticipate future growth for the erstwhile needle movers currently in development.
Now that they satisfied the REMS requirement they should be ready to sell hopefully next month after trademark objection is moot. Nas may mention it on conference call.
Tagi Pharma is a wholly owned subsidiary of Precision Dose. Same address.
He took the Express Train that he named for himself.
That 50 million share day was probably 10% of the float before NH converted his shares. That being said, I think a new group of investors have found this gem. As expected .20 appears to be a resistance level. Hard to predict where this goes when it is breached since there is no charting history at these levels for almost a decade.
AI leader in worldwide education.
Market cap of $20 M. RJH could take this private for $200 M a ten bager from here. The purchasers of the 8 million offering are long term players. Welcome to Shark Tank.
Sale is over. Purchases below .30 will look pretty good soon. There is always someone who knows more then you. Expect some news next week. It is rarely wrong to bet on companies owned by Billionaires. Warren, Elon and who is CEO here. Does anyone think he does not want this company that looks to be a major world wide educator to excel?
MMs on level 2 now have minimum bid /offer at 2500 shares as opposed to 5000 when stock is under .20 cents
Both things can be true. Fisher Asset Management had a tiny piece and Ken Fisher is a great investor. It will be interesting to see what they report for the 4th quarter holdings.
Notice the increased volume and share price appreciation since the poison pill expired in November. Hmmm.
The stay of all proceedings for a period of up to 6 months revolves around the Perdue v Accord Healthcare case where Perdue was claiming,that Accord infringed upon the Perdue OXYCONTIN patent. Accord won the case and Perdue has a pending appeal. The decision in the Appellate Court to either affirm or reverse the Accord victory will have an effect on similar issues in the Perdue case against Elite and hence all parties have agreed to a stay.
As an Elite shareholder, the hope and expectation is that Accord will prevail in the Appellate Court and unless Perdue can appeal to a higher Court, Elite can move to lift the stay and make a motion to dismiss the Perdue claim based upon Stare Decisis, a fancy legal term for the issue has already been decided.
Meanwhile since there is a stay, all proceedings, including discovery have been halted so Elite will save on the legal fee and hopefully Perdue's claim will be moot. THe needle is starting to move our way.
5 days ago you were predicting .10 by early February. Now looking for a big move up. You are apparently a person of little conviction. Meanwhile someone spent 8 million in one shot after we have to assume a good due diligence. Strong Buy here.
Isn't a berdbrain the antithesis of a genius? Good luck to you and your flock.
Jammie is suspended until May 4 2024. At that time he will be able to tell you stock is overvalued at .35 and it is going to a nickel after the announcement of the reverse split.
Even a stopped watch is right twice a day. Stock looks strong to me but you have no clue. Expect that the $8m stock deal to close today and the stock to move up based on fundamentals and a strong er next month.
Only 148 miles or 2.5 hours from Elite headquarters to Atlantic City. We can all meet in June at the hotel and drive to the meeting in a Limo. Eatman and Jammie can pay for it.
There have been no sizable block trades. I think jour trading after a nice pump fest for the past few days. Never try to outsmart the big boys. You ain't seen nothing yet.
Today should be a good test. The Trend is your Friend.
With 5 million share volume on no news and on a bad day for the market, I think we can posture that new investors are finding this stock. Long time, big holders here are apparently holding thud creating shortage on the offer. Without institutional ownership due to caveats in their charter, volume here has historically been a modest 1-2M shares per day.
Currently there is only one institution, Fisher Asset Management, which holds a mere 82,000 shares per their last report at the end of September. Perhaps they are accounting for the new volume.
Another possibility is that this is front running some major event soon to be announced since the ER is still a month away.
Excellent information regarding trademark dispute. The launch of Sabril appears to be imminent.
You can add others who missed the boat, but dying is an excellent excuse for some you cite. Stay relatively healthy and the rest is much easier.
The prediction of revenue of $145M for this calendar year is way too optimistic unless the DEA gives Elite a massive increase to its quota. While the Prasco/Burel manufacturing deal is nice, investors have no way of evaluating that source of income until we see the results from a few quarters. To reach your guestimate, Elite would need to average between $38-40M per quarter which is more than double the highest quarter last reported.
That being said, if the second quarter results match or exceed the record 1st quarter of $14.9 million, this stock should continue its strong upward trend. Over hyping may cause weak hand holders to fold way too early.
Don't worry, be happy.
The amount of adderall, its main product as you noted, that Elite can sell, is controlled by quotas set by the DEA. There has been an indication that the DEA has increased the quota to ease the shortage and Nasrat has reported that he had elite apply for the quota of Dexcel since as previous sellers of brand label adderall they were unfamiliar with the procedure.
That being said, a revenue report at or above 15 million would be great. As my mother would say, not good when your eyes are bigger than your mouth.
Google search reveals the cost of 50 500mg tablets of Sabril is $1,839. Expect that pyros launches sometime this year.
It will be interesting to see if elite continues to report revenues in line with the last 14.5m quarter. If so a 60-75m yearly revenue before any additional approvals would be attainable. Watch for average daily volume to exceed 2M as new blood comes in.
Update of the trademark dispute between Pyros Vigpoder application and Upsher Smith whose Vigabatrin generic is trademarked as Vigadrone.
Pyros published its trademark application in September and on 10/17/23 Upsher Smith made a request for an extension of time to file an opposition to the application apparently based upon the similarity of the names. I can find no follow up to indicate that Upsher actually decided to oppose the Pyros trademark designation.
I intend to email the attorney for Pyros, Cheryl Clarkin from the firm of Adler Pollock in Providence RI after the MLK holiday to see if the time to oppose has expired.
For newcomers it should be noted that Elite developed the Pyros generic and then sold it to Pyros with an agreement that Elite would be their sole manufacturer. This drug, used primarily for children with epilepsy, is highly toxic and requires REMs treatment to warn users of the many side effects. This along with the trademark dispute has caused a delay of the pyros launch.
The Vigabatrin drug is very expensive and once launched, I expect the manufacturing costs to be an additional source of revenue for Elite.
Thanks to the King for bringing this development to the Boards attention.
Have faith.
A whole lot of shakin going on. Excellent due diligence on this board. Slowly we turn, step by step, inch by inch.
Sweet Little Sixteen. We Reelin and Rockin.
Don't worry. Be happy.